Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Biomarkers | Research

Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma

Authors: Xiang Li, Zigang Ding, Yun Tong

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Background

Small ubiquitin-like modifier (SUMO) modification is increasingly recognized as critical in tumorigenesis and progression. This study identifies biomarkers linked to SUMOylation in papillary thyroid carcinoma (PTC), aiming to advance therapeutic and prognostic strategies.

Methods

Employing PTC datasets and SUMO related genes (SRGs), we utilized univariate Cox regression for prognosis-related SRGs, conducted differential expression analyses, and integrated findings to pinpoint candidate genes. These genes underwent further validation through survival, gene set enrichment, immune infiltration, and drug sensitivity analyses, including external validation via quantitative RT-qPCR. In our final step, we conducted immunohistochemical staining on tumor samples from PTC patients at our center and integrated this with their clinical data to validate BMP8A’s effectiveness in predicting recurrence in PTC.

Results

Three biomarkers—BMP8A, RGS8, and SERPIND1—emerged as significant. Gene Set Enrichment Analysis (GSEA) showed their involvement in immune-related pathways, with differential immune infiltration patterns and drug response correlations observed, underscoring their potential for targeted therapy. Lastly, we validated the efficacy of BMP8A in predicting the recurrence of PTC in patients using clinical and pathological data from our center.

Conclusion

The study identifies BMP8A, RGS8, and SERPIND1 as key biomarkers associated with SUMOylation in PTC. Their linkage to immune response and drug sensitivity highlights their importance as targets for therapeutic intervention and prognosis in PTC research.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA: Cancer J Clin. 2020;70:7–30.
2.
Chen D, Lang B, McLeod D, Newbold K. M. Haymart. Thyroid cancer. Lancet (London England). 2023;401:1531–44.PubMedCrossRef
3.
Derwich A, Sykutera M, Bromińska B, Andrusiewicz M, Ruchała M. Sawicka-Gutaj. Clinical implications of mTOR expression in papillary thyroid Cancer-A systematic review. Cancers. 2023;15:1665.PubMedPubMedCentralCrossRef
4.
Bogdanova T, Saenko V, Brenner A, Zurnadzhy L, Rogounovitch T, Likhtarov I, Masiuk S, Kovgan L, Shpak V, Thomas G, Chanock S, Mabuchi K, Tronko M, Yamashita S. Comparative histopathologic analysis of radiogenic and sporadic papillary thyroid carcinoma: patients born before and after the chernobyl accident. Thyroid: Official J Am Thyroid Association. 2018;28:880–90.CrossRef
5.
Hou D, Xu H, Yuan B, Liu J, Lu Y, Liu M, Qian Z. Effects of active localization and vascular preservation of inferior parathyroid glands in central neck dissection for papillary thyroid carcinoma. World J Surg Oncol. 2020;18:95.PubMedPubMedCentralCrossRef
6.
Zhang K, Li C, Liu J, Tang X, Li Z. DNA methylation alterations as therapeutic prospects in thyroid cancer. J Endocrinol Investig. 2019;42:363–70.CrossRef
7.
Saravana-Bawan B, Bajwa A, Paterson J, McMullen T. Active surveillance of low-risk papillary thyroid cancer: a meta-analysis. Surgery. 2020;167:46–55.PubMedCrossRef
8.
Hartl D, Hadoux J, Guerlain J, Breuskin I, Haroun F, Bidault S, Leboulleux S, Lamartina L. Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2019;33:101281.PubMedCrossRef
9.
Hendriks I, Vertegaal A. A comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell Biol. 2016;17:581–95.PubMedCrossRef
10.
11.
12.
Han Z, Feng Y, Gu B, Li Y, Chen H. The post-translational modification, SUMOylation, and cancer (review). Int J Oncol. 2018;52:1081–94.PubMedPubMedCentral
13.
Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi P, Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell. 2005;9:769–79.PubMedCrossRef
14.
Bergink S, Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature. 2009;458:461–7.PubMedCrossRef
15.
Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, Yue Z, Li W, Xin Z, Zheng Q, Cao Y, Pan J, Dong B, Cheng J, Wang Q. Xue W. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nat Commun. 2021;12:1812.PubMedPubMedCentralCrossRef
16.
17.
Wang K, Zhou W, Cai Q, Cheng J, Cai R, Xing R. SUMOylation of KLF4 promotes IL-4 induced macrophage M2 polarization. Cell Cycle (Georgetown Tex). 2017;16:374–81.PubMedCrossRef
18.
19.
Coleman A, Bose A, Mitra S. Metagenomics data visualization using R. Methods in molecular biology. (Clifton N J). 2023;2649:359–92.
20.
Wilkerson M, Hayes D. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinf (Oxford England). 2010;26:1572–3.
21.
22.
23.
Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J, Müller M. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.PubMedPubMedCentralCrossRef
24.
Sturm G, Finotello F, List M. Immunedeconv: an R Package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods in molecular biology. (Clifton N J). 2020;2120:223–32.
25.
Geeleher P, Cox N, Huang R. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9:e107468.PubMedPubMedCentralCrossRef
26.
Donaldson L, Yan F, Morgan P, Kaczmar J, Fernandes J, Nguyen S, Jester R, Day T. Hobnail variant of papillary thyroid carcinoma: a systematic review and meta-analysis. Endocrine. 2021;72:27–39.PubMedCrossRef
27.
Harries V, Wang L, McGill M, Xu B, Tuttle R, Wong R, Shaha A, Shah J, Ghossein R, Patel S. Ganly I. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? Surgery. 2020;167:10–7.PubMedCrossRef
28.
Tuccilli C, Baldini E, Sorrenti S, Di Gioia C, Bosco D, Ascoli V, Mian C, Barollo S, Rendina R, Coccaro C, Pepe M, Catania A, Bononi M, Tartaglia F, De Antoni E, D’Armiento M. Ulisse S. Papillary thyroid cancer is characterized by altered expression of genes involved in the sumoylation process. J Biol Regul Homeost Agents. 2015;29:655–62.PubMed
29.
Tang J, Tan M, Liao S, Pang M, Li J. Recent progress in the biology and physiology of BMP-8a. Connect Tissue Res. 2023;64:219–28.PubMedCrossRef
30.
Sethakorn N, Dulin N. RGS expression in cancer: oncomining the cancer microarray data. J Recept Signal Transduct Res. 2013;33:166–71.PubMedCrossRef
31.
Guo Q, Zhu L, Wang C, Wang S, Nie X, Liu J, Liu Q, Hao Y, Li X, Lin B. SERPIND1 affects the malignant biological behavior of epithelial ovarian cancer via the PI3K/AKT pathway: a mechanistic study. Front Oncol. 2019;9:954.PubMedPubMedCentralCrossRef
32.
Sagorny K, Chapellier M, Laperrousaz B. Maguer-Satta. [BMP and cancer: the Yin and Yang of stem cells]. Med Sci (Paris). 2012;28:416–22.PubMedCrossRef
33.
34.
Yu Y, Cai L, Wang X, Cheng S, Zhang D, Jian W, Wang T, Yang J, Yang K, Zhang C. BMP8A promotes survival and drug resistance via Nrf2/TRIM24 signaling pathway in clear cell renal cell carcinoma. Cancer Sci. 2020;111:1555–66.PubMedPubMedCentralCrossRef
35.
Katsuta E, Maawy A, Yan L, Takabe K. High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor–positive breast cancer. Oncol Rep. 2019;42:1413–21.PubMedPubMedCentral
36.
Liu K, Gao M, Qin D, Wang H, Lu Q. Serous BMP8A has clinical significance in the ultrasonic diagnosis of thyroid cancer and promotes thyroid cancer cell progression. Endocr Metab Immune Disord Drug Targets. 2020;20:591–8.PubMedCrossRef
37.
Hurst J, Hooks S. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol. 2009;78:1289–97.PubMedCrossRef
38.
39.
Bai M, Ke S, Yu H, Xu Y, Yu Y, Lu S, Wang C, Huang J, Ma Y, Dai W, Wu Y. Key molecules associated with thyroid carcinoma prognosis: a study based on transcriptome sequencing and GEO datasets. Front Immunol. 2022;13:964891.PubMedPubMedCentralCrossRef
40.
41.
Bergdorf K, Ferguson D, Mehrad M, Ely K, Stricker T. Weiss V. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment. endocrine-related cancer. 2019;26:601–14.PubMedPubMedCentralCrossRef
42.
Yang Z, Wei X, Pan Y, Xu J, Si Y, Min Z. Yu B. A new risk factor indicator for papillary thyroid cancer based on immune infiltration. Cell Death Dis. 2021;12:51.PubMedPubMedCentralCrossRef
43.
Xie Z, Li X, He Y, Wu S, Wang S, Sun J, He Y, Lun Y. Zhang J. Immune cell confrontation papillary thyroid carcinoma microenvironment. Front Endocrinol. 2020;11:570604.
44.
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nature reviews. Mol cell Biology. 2010;11:329–41.
45.
Yue Q, Khojasteh S, Cho S, Ma S, Mulder T, Chen J, Pang J, Ding X, Deese A, Pellet J, Siebers N, Joas L, Salphati L, Ware J. Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans. Xenobiotica. 2021;51:796–810.PubMedCrossRef
46.
Sarker D, Ang J, Baird R, Kristeleit R, Shah K, Moreno V, Clarke P, Raynaud F, Levy G, Ware J, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke J, Lackner M, Yan Y, Friedman L, Kaye S, Derynck M, Workman P, de Bono J. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin cancer Research: Official J Am Association Cancer Res. 2015;21:77–86.CrossRef
47.
Pictilisib stalls. Advanced ER+/PR + breast cancer. Cancer Discov. 2015;5:OF5.
48.
Krop I, Mayer I, Ganju V, Dickler M, Johnston S, Morales S, Yardley D, Melichar B, Forero-Torres A, Lee S, de Boer R, Petrakova K, Vallentin S, Perez E, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811–21.PubMedPubMedCentralCrossRef
49.
Khalafi S, Zhu S, Khurana R, Lohse I, Giordano S, Corso S, Al-Ali H, Brothers S, Wahlestedt C, Schürer S, El-Rifai W. A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. Translational Oncol. 2022;15:101260.CrossRef
50.
De Wolf E, De Wolf C, Richardson A. ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. Oncol Lett. 2018;15:1979–84.PubMed
51.
Shapiro G, LoRusso P, Kwak E, Pandya S, Rudin C, Kurkjian C, Cleary J, Pilat M, Jones S, de Crespigny A, Fredrickson J, Musib L, Yan Y, Wongchenko M, Hsieh H, Gates M, Chan I, Bendell J. Phase ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Investig New Drugs. 2020;38:419–32.CrossRef
52.
Burrows N, Babur M, Resch J, Ridsdale S, Mejin M, Rowling E, Brabant G, Williams K. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. J Clin Endocrinol Metab. 2011;96:E1934–1943.PubMedCrossRef
53.
Burrows N, Telfer B, Brabant G, Williams K. Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and hypoxia-inducible factor-1 activity. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2013;108:548–53.CrossRef
54.
Kandil E, Tsumagari K, Ma J, Abd Elmageed Z, Li X, Slakey D, Mondal D, Abdel-Mageed A. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. J Surg Res. 2013;184:898–906.PubMedCrossRef
55.
Ywata de Carvalho A, Kohler HF, Gomes CC, Vartanian JG, Kowalski LP. Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients. Acta Otorhinolaryngol Ital. 2021;41:236–42.PubMedPubMedCentralCrossRef
56.
Hassan A, Razi M, Riaz S, Khalid M, Nawaz MK, Syed AA, Bashir H. Survival analysis of papillary thyroid carcinoma in relation to stage and recurrence risk: a 20-year experience in Pakistan. Clin Nucl Med. 2016;41:606–13.PubMedCrossRef
Metadata
Title
Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma
Authors
Xiang Li
Zigang Ding
Yun Tong
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03323-3

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

Novel lncRNAs LINC01221, RP11-472G21.2 and CRNDE are markers of differential expression in pediatric patients with T cell acute lymphoblastic leukemia

Research

AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway

Research

METTL14 enhances the m6A modification level of lncRNA MSTRG.292666.16 to promote the progression of non-small cell lung cancer

Research

YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance

Research

Integrated analysis of disulfidptosis-related immune genes signature to boost the efficacy of prognostic prediction in gastric cancer

Research

RhoB expression associated with chemotherapy response and prognosis in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits